COMMUNIQUÉS West-GlobeNewswire

Natural Alternatives International, Inc. Announces 2025 Q1 Results
13/11/2024
CARLSBAD, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer, and marketer of customized nutritional supplements, today [...]
Telix ADSs Commence Trading on Nasdaq
13/11/2024
MELBOURNE, Australia, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) announces that its American Depository Shares (ADSs) have commenced trading on the Nasdaq [...]
Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
13/11/2024
Successful go-public transaction and over $475 million raised this year provides cash runway through multiple clinical inflection points ORKA-001 non-human primate (NHP) pharmacokinetic and in vitro potency data, [...]
SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update
13/11/2024
– Pre-specified Events to Trigger Interim Analysis of Phase 3 REGAL Study in Patients with Acute Myeloid Leukemia (AML) Remains on Track for Q4 2024 – – Data from the Phase 2a Trial of SLS009 in Relapsed/Refractory AML [...]
Voting Rights and Shares Capital of the Company
13/11/2024
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Nov. 13, 2024 (GLOBE NEWSWIRE [...]
INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
13/11/2024
Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers PARIS, 13 nov. 2024 (GLOBE NEWSWIRE) -- Paris, France, le 13 novembre 2024 Place de cotation [...]
NurExone Biologic Secures EMA Orphan Status for ExoPTEN in Spinal Cord Injury, Accelerating Pathway to European Markets
13/11/2024
TORONTO and HAIFA, Israel, Nov. 13, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (" NurExone " or the " Company "), a biopharmaceutical company developing exosome-based [...]
GENFIT Announces Corporate Updates and Upcoming Participation at The Liver Meeting® 2024
13/11/2024
PBC program (licensed to Ipsen): Ipsen to present new data on elafibranor at The Liver Meeting® 2024 Launch of Iqirvo® (elafibranor) 1 on track with expectations; encouraging feedback from healthcare providers and [...]
GENFIT fait un point d’actualité sur ses activités à l’occasion de sa participation prochaine à l’AASLD Liver Meeting® 2024
13/11/2024
Programme PBC (sous licence Ipsen) : Ipsen présentera de nouvelles données sur elafibranor à l’AASLD Liver Meeting® 2024 Lancement commercial d’Iqirvo® (elafibranor) 1 conforme aux attentes ; retours encourageants des [...]
Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates
13/11/2024
Positive long-term extension data highlighting the differentiated profile of deucrictibant for the prevention and treatment of HAE attacks presented at recent medical congresses Intend to engage in clinical development [...]
Integra’s DuraSeal® Dural Sealant Saves Healthcare Costs According to an Economic Evaluation Published in the Journal of Comparative Effectiveness Research
13/11/2024
The health economic analysis, conducted in five European countries, shows that hospitals can reduce costs of cerebrospinal fluid leaks after posterior cranial fossa surgeries by using DuraSeal dural sealant instead of [...]
Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements
13/11/2024
– Presented data at EADV supporting potential of ESK-001 as differentiated oral treatment in immune-mediated diseases through maximal TYK2 inhibition – – Continued to advance three clinical programs, including global [...]
ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2024
13/11/2024
PORTLAND, Maine, Nov. 13, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and [...]
AEON Biopharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update
13/11/2024
– Held biosimilar advisory meeting with FDA in Q3 2024, and aligned on next steps for a 351(k) regulatory pathway to approval for ABP-450 (prabotulinumtoxinA) as a biosimilar utilizing BOTOX ® (onabotulinumtoxinA) as [...]
Akero Therapeutics to Present at the Jefferies London Healthcare Conference
13/11/2024
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked [...]
4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones
13/11/2024
Presented positive interim data for 4D-150 in wet age-related macular degeneration (wet AMD) from PRISM Phase 1/2 clinical trial highlighting robust and durable clinical activity across diverse patient populations and [...]
Invizyne’s Nasdaq IPO Marks New Era of Biomanufacturing
13/11/2024
Underlying technology demonstrates the use of enhanced enzyme systems outside of cells can bypass many of the limitations associated with traditional cell-based synthetic biology Monrovia, CA, Nov. 13, 2024 (GLOBE [...]
Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates
13/11/2024
- Announced Positive Initial Data, Including Complete and Partial Responses, with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients - - Granted FDA Orphan Drug Designation for IMM-1-104 [...]
Tonix Pharmaceuticals Announces Poster Presentation at the American College of Rheumatology (ACR) Convergence 2024 Annual Meeting
13/11/2024
CHATHAM, N.J., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of [...]

Pages